Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02088203 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)
A Phase 1 study of Diabetes Prevention, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT02088203: Completed Phase 1 study of Diabetes Prevention, sponsored by Pennington Biomedical Research Center.
NCT02088203 is a Phase 1 study of Diabetes Prevention that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 64 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02088203, a Phase 1 study of Diabetes Prevention, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Safety and tolerability of a soy-protein Russian Tarragon complex versus a placebo.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Dose 1
- DIETARY_SUPPLEMENT Dose 2
- DIETARY_SUPPLEMENT Dose 0
- DIETARY_SUPPLEMENT Dose 3
- DIETARY_SUPPLEMENT Dose 4
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-02 |
| Est. Completion | 2018-05 |
| Phase | Phase 1 |
What the finished NCT02088203 record still lists
NCT02088203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Diabetes Prevention appearing as the primary indexed condition, and to 5 interventions - of which Dose 1 is the first listed.
NCT02088203 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT02088203 about?
NCT02088203 is a clinical study titled "Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)". Safety and tolerability of a soy-protein Russian Tarragon complex versus a placebo.
What is the current status of trial NCT02088203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2014-02. Estimated completion is 2018-05.
What conditions does trial NCT02088203 study?
This clinical trial studies the following conditions: Diabetes Prevention.
What interventions are being tested in trial NCT02088203?
The interventions under investigation include: Dose 1 (DIETARY_SUPPLEMENT), Dose 2 (DIETARY_SUPPLEMENT), Dose 0 (DIETARY_SUPPLEMENT), Dose 3 (DIETARY_SUPPLEMENT), Dose 4 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02088203?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02088203 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Prevention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02088203's enrollment target sits among peer trials
64 808th of 2000 higher than 1,181 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia